Advertisement
Canada markets open in 7 hours 44 minutes

  • S&P/TSX

    21,708.44
    +52.39 (+0.24%)
     

  • S&P 500

    5,011.12
    -11.09 (-0.22%)
     

  • DOW

    37,775.38
    +22.07 (+0.06%)
     

  • CAD/USD

    0.7257
    -0.0007 (-0.09%)
     

  • CRUDE OIL

    84.53
    +1.80 (+2.18%)
     

  • Bitcoin CAD

    85,658.27
    +1,075.43 (+1.27%)
     

  • CMC Crypto 200

    1,282.11
    +396.58 (+43.35%)
     

  • GOLD FUTURES

    2,397.80
    -0.20 (-0.01%)
     

  • RUSSELL 2000

    1,942.96
    -4.99 (-0.26%)
     

  • 10-Yr Bond

    4.6470
    +0.0620 (+1.35%)
     

  • NASDAQ futures

    17,356.50
    -190.75 (-1.09%)
     

  • VOLATILITY

    18.00
    -0.21 (-1.15%)
     

  • FTSE

    7,877.05
    +29.06 (+0.37%)
     

  • NIKKEI 225

    37,164.85
    -914.85 (-2.40%)
     

  • CAD/EUR

    0.6823
    +0.0002 (+0.03%)
     

TrovaGene (TROV) Enters Oversold Territory

Zacks Equity Research

TrovaGene Inc ’s ( TROV ) share price has entered into oversold territory with an RSI value of 28.9. The Zacks Consensus Estimate for TrovaGene for the full year period has improved 13 cents over the past two months to -91 cents per share. Currently, TrovaGene has a Zacks Rank #1 (Strong Buy), suggesting that now might be a good time to get in on ( TROV ) after its recent drop.



TROVAGENE NEW (TROV): Free Stock Analysis Report


Zacks Investment Research